| Description |
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers[1][2].
|
| Related Catalog |
|
| In Vitro |
Losatuxizumab (0.001 nM-100 nM) 可与表达 EGFRvIII 的细胞系 U87MGde2-7 结合[1]。 Losatuxizumab 抑制 NR6 huEGFRC271A,C283A 细胞系中 EGF 介导的 EGFR 磷酸化，IC50 为 1.2 nM[2]。
|
| In Vivo |
Lorigerlimab 在多种表达野生型 EGFR 的鳞状细胞癌异种移植模型中均具有抗肿瘤活性[1]。 Lorigerlimab (40 mg/kg, 腹腔注射) 显着抑制小鼠 U87MGde2-7 肿瘤的生长[1]。 Lorigerlimab (10 和 40 mg/kg，腹腔注射) 在 PDX GBM 模型 (SN0207 肿瘤) 中延长生存期并降低肿瘤中 pEGFR 水平[1]。 Animal Model: PDX GBM model (SN0207 tumor)[1] Dosage: 40 mg/kg Administration: i.p. Result: Prolonged survival rate, and reduced levels of pEGFR in tumor.
|
| References |
[1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. [2]. Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9.
|
